Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication
July 28, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
May 21, 2015 16:05 ET
|
Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
Achieved statistical significance on...
Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer
May 18, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application
April 28, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Presents AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference
April 27, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients
April 20, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
March 18, 2015 16:14 ET
|
Otonomy, Inc.
SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Corporate Update
March 12, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, March 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update
November 12, 2014 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...